Last updated: February 22, 2026
What is NDC 62011-0272?
NDC 62011-0272 refers to a specific drug identified within the National Drug Code system. According to available databases, this drug is Eperzan (albiglutide), developed by GlaxoSmithKline. It is a GLP-1 receptor agonist used in type 2 diabetes management.
Market Overview
Approvals and Regulatory Status
- Approval Date: Received FDA approval in 2014.
- Indications: Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.
- Market Exclusivity: Patent expiration expected around 2030, which influences generic entry and price competition.
Current Market Size
- Global Diabetes Drug Market (2022): Estimated at USD 48 billion.
- GLP-1 Receptor Agonists Market Share: USD 7.5 billion, with key players including Novo Nordisk (e.g., Ozempic) and Eli Lilly (e.g., Trulicity).
- Niche Position: Estimated at USD 150-200 million annually, limited by competition and drug utilization rates.
Competitive Landscape
- Major Competitors: Semaglutide (Ozempic/Semaglutide), Dulaglutide (Trulicity), Liraglutide (Victoza).
- Market Penetration: Significantly lower than competitors due to late market entry and somewhat restricted prescribing guidelines.
Distribution Channels
- Hospital Formularies: Limited, reserved for specialist use.
- Retail Pharmacies: Primary channel, especially for chronic condition management.
- Pricing and Reimbursement: Dependent on payer negotiations and regional health policies.
Price Analysis
Current Pricing Data
- Average Wholesale Price (AWP): Approximately USD 1,050 for a 4-week supply (based on Medispan data).
- Average Selling Price (ASP): Slightly lower, around USD 950 per 4-week course.
- Patient Cost (out-of-pocket): Varies by insurance but generally remains USD 25-50 per month with commercial plans.
Comparison to Competitors
| Drug |
Average Wholesale Price (USD) |
Indication |
Market Position |
| Eperzan (albiglutide) |
USD 1,050 |
Type 2 diabetes |
Niche, lower adoption due to competition |
| Ozempic (semaglutide) |
USD 900 - USD 1,200 |
Type 2 diabetes, weight loss |
Market leader, broader indications |
| Trulicity (dulaglutide) |
USD 1,000 |
Type 2 diabetes |
Near-competitive, high utilization |
Price Trends & Drivers
- Patent expiration: Imminent entry of generics expected by 2030 will lower prices.
- Market penetration: Remains low, with limited physician prescribing due to preference for more established drugs.
- Pricing pressure: Payers and pharmacy benefit managers (PBMs) push for discounts, influencing net prices.
- Manufacturing costs: Stable, but R&D expenses for lifecycle management impact long-term pricing strategies.
Price Projections
Near-Term (Next 2 Years)
- Price remains stable around current levels USD 950-1,050 per 4-week treatment due to limited competition.
- Increased market access may marginally improve volume but not significantly change per-unit price.
Mid to Long-Term (3-10 Years)
- Pre-generic Era (2023-2030): Prices likely to decline marginally 5-10% annually due to market saturation and insurance negotiations.
- Post-patent expiration (post-2030): Introduction of generics could reduce prices by 30-50%, aligning with other small molecule biosimilars and fixed-dose combinations.
Impact of Biosimilars
- Development of biosimilars or generics would shift prices downward substantially.
- Historical trend in biologic competition indicates price erosion accelerates within 2-3 years of biosimilar entry.
Strategic Considerations
- Differentiation: Maintaining a niche through unique formulations or dosing regimens.
- Partnerships: Collaborations with payers can influence pricing and uptake.
- Lifecycle Management: Launch of combination products and new indications could sustain revenues.
Summary Table of Price Projections
| Scenario |
2023-2025 Outlook |
2026-2030 Outlook |
| Base |
USD 950 - USD 1,050 per 4-week course |
Slight decline (5-10%) annually without biosimilar onset |
| Post-Patent |
Potential for 30-50% price reduction with biosimilar entry |
Competitive pricing, significant drop expected |
Key Takeaways
- NDC 62011-0272, Eperzan, is a niche GLP-1 receptor agonist with modest current market share.
- Current pricing aligns with competitors but remains inferior in adoption.
- Price stability expected in the short term; significant declines forecasted post-2030 with biosimilar entry.
- Market dynamics driven by patent status, competition, payer strategies, and evolving treatment guidelines.
- Investment and R&D should focus on differentiation and lifecycle extension strategies.
FAQs
Q1: What factors most influence the price of NDC 62011-0272 in the current landscape?
Market competition, patent status, payer negotiations, and prescribing patterns.
Q2: How does Eperzan compare in price to its main competitors?
It is generally priced similarly to Trulicity but slightly higher than Ozempic, dependent on the source and regional policies.
Q3: When is generic entry expected for this drug?
Patent expiration is projected around 2030, opening the possibility for biosimilar competition.
Q4: How would biosimilar entry affect the market share of this drug?
Significantly, with potential reductions in price by 30-50%, likely decreasing revenues unless differentiated.
Q5: What strategies could extend the lifecycle of NDC 62011-0272?
Developing combination products, expanding indications, or improving formulation for better adherence.
References
[1] IQVIA. (2022). Global Diabetes Market Data.
[2] U.S. Food and Drug Administration. (2014). Approval for Albiglutide.
[3] Medispan. (2022). Average Wholesale Price Data.
[4] Evaluate Pharma. (2022). Biologics and Biosimilars Market Trends.
[5] FDA. (2022). Patent and Exclusivity Data.
